肿瘤防治研究2012，Vol.39Issue(9)：1132-1135,4.DOI:10.3971/j.issn.1000-8578.2012.09.019
中等剂量卡培他滨单药治疗转移性乳腺癌的疗效及安全性
Efficacy and Safety of Moderate-dose Capecitabine in Treatment of Metastatic Breast Cancer
严颖 1任军 1林晓琳 1宛凤玲 1邸立军1
作者信息
- 1. 100142北京,北京大学肿瘤医院暨北京市肿瘤防治研究所乳腺内科 恶性肿瘤发病机制及转化研究教育部重点实验室
- 折叠
摘要
Abstract
Objective To determine activity and safety of capecitabine at a moderate dose of 2000 mg/(m2 · d) for metastatic breast cancer. Methods In this retrospective trial, 43 metastatic breast cancer patients received first-line capecitabine 2 000 mg/m2 on days 1 —14 every 3 weeks. Results 43 metastatic breast cancer patients received mean 8 cycles of capecitabine therapy. Median PFS was 7. 1 months (95% CI:5.8~8.4). There were no difference among the first line,the second line and third line treatment 7. 1 months,6. 1 months, and 8. 1 months respectively (P = 0. 390). Patients pretreated with both anthracy-cline and taxane therapy had a significantly shorter PFS(6. lmonths vs. 7. 1 months, P = 0. 038) , but pa-tients>65 years achieved a significantly longer PFS(8. 1 months vs. 6. 1 months,P= 0. 045). Ninteen cases (44. 2%) had hand-foot syndrome, a main toxicity. Conclusion Capecitabine at a moderate dose of 2 000 mg/(m2 · d)is active and well-tolerated for metastatic breast cancer.
关键词
中等剂量/卡培他滨/转移性乳腺癌Key words
Moderate-dose/Capecitabine/Metastatic breast cancer分类
医药卫生引用本文复制引用
严颖,任军,林晓琳,宛凤玲,邸立军..中等剂量卡培他滨单药治疗转移性乳腺癌的疗效及安全性[J].肿瘤防治研究,2012,39(9):1132-1135,4.
